BTLA and B-cell chronic lymphocytic leukemia: Also, elevated BTLA expression in NK and T cells from CLL was shown to correlate with a shorter time to treatment as well as a diminished anti-tumor response, while treatment with an anti-BTLA blocking antibody restored anti-leukemic activity by promoting in vitro Th1 cytokine production and cytotoxicity [31,32].